Karyopharm Therapeutics
Quarterly Financials
| Values in thousands | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
Revenue | $33,432 | $35,066 | $34,079 | $44,044 |
Gross Profit | 32,347 | 33,709 | 32,595 | 41,931 |
EBITDA | -53,882 | -9,826 | -89,627 | -22,560 |
EBIT | -53,879 | -9,838 | -89,646 | -22,638 |
Net Income | -67,023 | -22,392 | -102,198 | -33,127 |
Net Change In Cash | 33,432 | 35,066 | 34,079 | 44,044 |
Free Cash Flow | -24,931 | -22,728 | -11,828 | -5,860 |
Cash | 54,980 | 90,850 | 60,540 | 37,672 |
Basic Shares | 28,938 | 24,715 | 18,215 | 8,669 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $146,067 | $145,237 | $146,033 | $157,074 |
Gross Profit | 140,118 | 139,230 | 141,091 | 151,861 |
EBITDA | -149,851 | -38,603 | -118,423 | -139,305 |
EBIT | -150,147 | -38,943 | -118,953 | -139,926 |
Net Income | -196,039 | -76,422 | -143,099 | -165,291 |
Net Change In Cash | 146,067 | 145,237 | 146,033 | 157,074 |
Cost of Revenue | -60,072 | |||
Free Cash Flow | -75,369 | -127,628 | -92,723 | -149,672 |
Cash | 60,540 | 62,476 | 52,231 | 135,188 |
Basic Shares | 10,935 | 8,124 | 7,614 | 5,458 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | -$2.32 |
2026-03-31 | -$1.24 |
2025-12-31 | -$2.23 |
2025-09-30 | -$3.82 |